

Figure S1. Nucleoprotein-specific IgG. IgG anti-nucleoprotein (N) titers monitored in samples collected at month 3 (M3) and 9 (M9) in each participant to the study. A negative (K-) and positive (K+) controls (WHO International Reference Panel of anti-SARS-CoV-2 immunoglobulin, NIBSC code 20/144 and 20/142 respectively) were included as reference. Antibody titres are expressed as the reciprocal of the dilution of sample reporting a double OD value compared to the background.




Figure S2. Manual analysis of total B cells subsets. Flow cytometry analysis of live CD19^{+/low} B cells, according to the expression of IgD *versus* CD27 (CD27⁺IgD⁻ switched memory, Ig-sw; CD27⁺IgD⁺ unswitched, Unsw; CD27⁻IgD⁻ double negative, DN; and CD27⁻IgD⁺ *naïve*), CD21 *versus* CD27 (CD27⁺CD21⁻ activated, Activ; CD27⁺CD21⁺ resting, Rest; CD27⁻CD21⁻ atypical, Atyp; and CD27⁻CD21⁺ naïve) and IgG⁺, IgA⁺, IgD⁺IgM⁺, IgM⁺ only.